Absci Corporation

NasdaqGS ABSI

Absci Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -83.27 M

Absci Corporation EBITDA is USD -83.27 M for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Absci Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -98.57 M, a -21.87% change year over year.
Absci Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -80.88 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years